High Survival Rate After Two-stage Resection of Advanced Colorectal Liver Metastases: Response-based Selection and Complete Resection Define Outcome

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2011 Jan 26

PMID 21263087

Citations 141

Authors

Antoine Brouquet

Eddie K Abdalla

Scott Kopetz

Christopher R Garrett

Michael J Overman

Cathy Eng

Andreas Andreou

Evelyne M Loyer

David C Madoff

Steven A Curley

Jean-Nicolas Vauthey

Affiliations

Soon will be listed here.

Abstract

Purpose: Prolonged survival after two-stage resection (TSR) of advanced colorectal liver metastases (CLM) may be the result of selection of best responders to chemotherapy. The impact of complete resection in this well-selected group is controversial.

Patients And Methods: Data on 890 patients undergoing resection and 879 patients who received only chemotherapy for CLM were collected prospectively. We used intent-to-treat analysis to evaluate the survival of patients who underwent TSR. Additionally, we evaluated a cohort of nonsurgically treated patients selected to mirror the TSR population: colorectal metastases with liver-only disease, objective response to chemotherapy, and alive 1 year after chemotherapy initiation.

Results: Sixty-five patients underwent the first stage of TSR; 62 patients fulfilled the inclusion criteria for the medical group. TSR patients had a mean of 6.7 ± 3.4 CLM with mean size of 4.5 ± 3.1 cm. Nonsurgical patients had a mean of 5.9 ± 2.9 CLM with mean size of 5.4 ± 3.4 cm (not significant). Forty-seven TSR patients (72%) completed the second stage. Progression between stages was the main cause of noncompletion of the second stage (61%). After 50 months median follow-up, the 5-year survival rate was 51% in the TSR group and 15% in the medical group (P = .005). In patients who underwent TSR, noncompletion of TSR and major postoperative complications were independently associated with worse survival.

Conclusion: TSR is associated with excellent outcome in patients with advanced CLM as a result of both selection by chemotherapy and complete resection of metastatic disease.

Citing Articles

Propensity Score-Matched Analysis of Liver Venous Deprivation and Portal Vein Embolization Before Planned Hepatectomy in Patients with Extensive Colorectal Liver Metastases and High-Risk Factors for Inadequate Regeneration.

Haddad A, Khavandi M, Lendoire M, Acidi B, Chiang Y, Gupta S Ann Surg Oncol. 2024; 32(3):1752-1761.

PMID: 39633174 DOI: 10.1245/s10434-024-16558-1.

CEA Rebound After Discontinuation of Pre-Hepatectomy Chemotherapy Predicts Worse Outcomes After Resection of Colorectal Cancer Liver Metastases.

Haddad A, Lendoire M, Uppal A, Maki H, Folkert I, Wang Y Ann Surg Oncol. 2024; 32(2):1021-1032.

PMID: 39516416 PMC: 11773633. DOI: 10.1245/s10434-024-16370-x.

Smart Operating Room in Digestive Surgery: A Narrative Review.

Laterza V, Marchegiani F, Aisoni F, Ammendola M, Schena C, Lavazza L Healthcare (Basel). 2024; 12(15).

PMID: 39120233 PMC: 11311806. DOI: 10.3390/healthcare12151530.

Partial hepatectomy accelerates colorectal metastasis by priming an inflammatory premetastatic niche in the liver.

Luenstedt J, Hoping F, Feuerstein R, Mauerer B, Berlin C, Rapp J Front Immunol. 2024; 15:1388272.

PMID: 38919609 PMC: 11196966. DOI: 10.3389/fimmu.2024.1388272.

Surgical Resection in Colorectal Liver Metastasis: An Umbrella Review.

Milazzo M, Todeschini L, Caimano M, Mattia A, Cristin L, Martinino A Cancers (Basel). 2024; 16(10).

PMID: 38791928 PMC: 11120322. DOI: 10.3390/cancers16101849.

References

de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J . Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18(16):2938-47. DOI: 10.1200/JCO.2000.18.16.2938. View

Elias D, Lefevre J, Chevalier J, Brouquet A, Marchal F, Classe J . Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2008; 27(5):681-5. DOI: 10.1200/JCO.2008.19.7160. View

Abdalla E, Vauthey J, Ellis L, Ellis V, Pollock R, Broglio K . Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004; 239(6):818-25. PMC: 1356290. DOI: 10.1097/01.sla.0000128305.90650.71. View

Blazer 3rd D, Kishi Y, Maru D, Kopetz S, Chun Y, Overman M . Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008; 26(33):5344-51. DOI: 10.1200/JCO.2008.17.5299. View

Kishi Y, Abdalla E, Chun Y, Zorzi D, Madoff D, Wallace M . Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry. Ann Surg. 2009; 250(4):540-8. DOI: 10.1097/SLA.0b013e3181b674df. View

Chun Y, Vauthey J, Boonsirikamchai P, Maru D, Kopetz S, Palavecino M . Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009; 302(21):2338-44. PMC: 4139149. DOI: 10.1001/jama.2009.1755. View

Kopetz S, Chang G, Overman M, Eng C, Sargent D, Larson D . Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009; 27(22):3677-83. PMC: 2720081. DOI: 10.1200/JCO.2008.20.5278. View

Van Cutsem E, Kohne C, Hitre E, Zaluski J, Chang Chien C, Makhson A . Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360(14):1408-17. DOI: 10.1056/NEJMoa0805019. View

Poultsides G, Servais E, Saltz L, Patil S, Kemeny N, Guillem J . Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol. 2009; 27(20):3379-84. PMC: 3646319. DOI: 10.1200/JCO.2008.20.9817. View

10.

Jaeck D, Oussoultzoglou E, Rosso E, Greget M, Weber J, Bachellier P . A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg. 2004; 240(6):1037-49. PMC: 1356519. DOI: 10.1097/01.sla.0000145965.86383.89. View

11.

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

12.

Wicherts D, Miller R, de Haas R, Bitsakou G, Vibert E, Veilhan L . Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann Surg. 2008; 248(6):994-1005. DOI: 10.1097/SLA.0b013e3181907fd9. View

13.

Chun Y, Vauthey J, Ribero D, Donadon M, Mullen J, Eng C . Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival. J Gastrointest Surg. 2007; 11(11):1498-504. DOI: 10.1007/s11605-007-0272-2. View

14.

Kishi Y, Zorzi D, Contreras C, Maru D, Kopetz S, Ribero D . Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol. 2010; 17(11):2870-6. DOI: 10.1245/s10434-010-1166-1. View

15.

Tsai S, Marques H, Jong M, Mira P, Ribeiro V, Choti M . Two-stage strategy for patients with extensive bilateral colorectal liver metastases. HPB (Oxford). 2010; 12(4):262-9. PMC: 2873649. DOI: 10.1111/j.1477-2574.2010.00161.x. View

16.

Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B . Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?. Ann Surg. 2004; 240(6):1052-61. PMC: 1356520. DOI: 10.1097/01.sla.0000145964.08365.01. View

17.

Douillard J, Cunningham D, Roth A, Navarro M, James R, Karasek P . Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000; 355(9209):1041-7. DOI: 10.1016/s0140-6736(00)02034-1. View

18.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

19.

Scheele J, Stang R, Altendorf-Hofmann A, Paul M . Resection of colorectal liver metastases. World J Surg. 1995; 19(1):59-71. DOI: 10.1007/BF00316981. View

20.

Charnsangavej C, Clary B, Fong Y, Grothey A, Pawlik T, Choti M . Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006; 13(10):1261-8. DOI: 10.1245/s10434-006-9023-y. View